Ezinyangeni eziyisishiyagalolunye ngemuva kokwethulwa e-US, isidakamizwa se-Alzheimer sika-Eisai kanye ne-Biogen iLeqembi ukuhlangana ukumelana okuphawulekayo ekutholweni kwayo okusabalele, ikakhulukazi ngenxa yokungabaza phakathi kwabanye odokotela mayelana nempumelelo yokwelapha lesi sifo sobuchopho esiwohlokayo.
Naphezu kokuba umuthi wokuqala ofakazelwe wehlisa ukuqhubekela phambili kwe-Alzheimer's, ukungabaza okugxilile phakathi kwabahlinzeki bezempilo mayelana nenani lokwelapha lesi simo kubonakala kuyisithiyo esikhulu.
Ochwepheshe be-Alzheimer ekuqaleni babelindele izinselele ezihlobene nephrothokholi efunwa uLeqembi, ehlanganisa ukuhlolwa okwengeziwe kokuxilonga, ukufakwa kabili ngenyanga, kanye nokuskena kobuchopho okuvamile ukuze kuqashwe imiphumela engemihle engaba namandla. Ngempela, lezi zidingo zibe nomthelela ekuthathweni kancane komuthi kusukela ekuvunyweni kwawo yi-US Food and Drug Administration, njengoba kufakazelwa izingxoxo nodokotela bezinzwa abangu-20 nodokotela bezifo ezifundeni ezihlukahlukene zase-US.
Ngokombiko weReuters, odokotela abayisikhombisa badalule ukuthi bayangabaza ukuthi banikeze uLeqembi, beveza ukungabaza ngokusebenza komuthi, izindleko zawo kanye nobungozi obuhambisana nawo. Ngaphezu kwalokho, iqembu lochwepheshe abayisithupha abahamba phambili kulo mkhakha libonise ukuthi "i-therapeutic nihilism" - umbono wokuthi i-Alzheimer's iyisimo esingenakunqobeka - inomthelela obaluleke kakhulu kunalokho okulindelekile ekunciphiseni isasasa phakathi kodokotela abanakekela abayinhloko, odokotela bezifo eziphuthumayo, nodokotela bezinzwa. Lokhu kungabaza kuthinta ukuzimisela kwabo ukudlulisela iziguli kongoti benkumbulo ukuze bathole ukwelashwa okungenzeka noLeqembi.
Abanye ochwepheshe bathi ukungabaza phakathi kwabanye odokotela kungase kusuke esikhathini eside sokungabaza esifiphaze ukusebenza kahle kokukhomba i-Alzheimer's protein beta amyloid ukuze kubambezeleke ukuqhubeka kwesifo. Ngaphambi kwemiphumela ekhuthazayo yocwaningo lukaLeqembi, abaningi emkhakheni wezokwelapha babheka lesi siqondiso socwaningo njengesingenazithelo.
Ukukhathazeka kuphakanyiswe abanye ochwepheshe bezokwelapha mayelana nemiphumela engemihle ye-Leqembi, njengokuvuvukala kobuchopho nokopha, ngaphezu kwezindleko ezihilelekile ngenani lentengo lonyaka lika-$26,500, ama-MRI avamile, kanye nokufakwa kabili ngenyanga.
I-Leqembi kwaba umuthi wokuqala oqondiswe ku-amyloid ukuthola ukugunyazwa okugcwele kwe-FDA ngemuva kokubonisa ukwehla okungama-27% ekwehleni kwengqondo phakathi kweziguli ze-Alzheimer's ezisesigabeni sakuqala phakathi nokuhlolwa komtholampilo. Ngaphandle kwenhloso yokuqala yokwelapha abantu baseMelika abayi-10,000 ekupheleni kukaMashi, bayizinkulungwane ezimbalwa kuphela ababeqale ukwelashwa ekupheleni kukaJanuwari, njengoba kubikiwe ngu-Eisai, umkhulumeli wakhe wenqabile ukuhlinzeka ngezibalo ezibuyekeziwe.
Ukwamukelwa kwemithi emisha, ngisho naleyo engadingi izinguquko ezibalulekile emisebenzini yezokwelapha, kuhamba kancane. Ucwaningo selukhombisile ukuthi kungathatha isilinganiso seminyaka eyi-17 ukuthi ucwaningo lwezempilo lube yinjwayelo. I-Alzheimer's ithinta abantu baseMelika abangaphezu kwezigidi eziyisi-6, nokho abangaphansi kwengxenye yodokotela bezinzwa base-US bancoma uLeqembi ezigulini zabo, ngokocwaningo lukaJanuwari empilweni. isayensi umcwaningi wemakethe uSpherix Global Insights.
Ibhalwe ngu Alius Noreika
